Giredestrant

DB19125InvestigationalSmall molecule

Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With Er-positive, Her2-negative Advanced...

Mechanism: Pharmacologically active on Estrogen receptor
Curator reviewed
Formula / weight: C₂₇H₃₁F₅N₄O · 522.564 g/mol (avg)
Also known as: (1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)-3-azetidinyl)amino)phenyl)-.beta.,.beta.-difluoro-1,3,4,9-tetrahydro-3-methyl-2h-pyrido(3,4-b)indole-2-propanol · 2h-pyrido(3,4-b)indole-2-propanol, 1-(2,6-difluoro-4-((1-(3-fluoropropyl)-3-azetidinyl)amino)phenyl)-.beta.,.beta.-difluoro-1,3,4,9-tetrahydro-3-methyl-, (1r,3r)- · 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido(3,4-b)indol-2-yl)-2,2-difluoropropan-1-ol
Code names: GDC-9545 · RG6171 · RO-7197597

Resolves to

Compound

UNII28P3DU6DB3CAS1953133-47-5ChEMBLCHEMBL4650316

Structure

InChIKeyGQCXHIKRWBIQMD-AKJBCIBTSA-NSMILESC[C@@H]1CC2=C(NC3=CC=CC=C23)[C@H](N1CC(F)(F)CO)C1=C(F)C=C(NC2CN(CCCF)C2)C=C1F

Targets

P03372ESR1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

23Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Giredestrant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account